NTHI
What one share of Neonc Technologies Holdings holds
Pharmaceutical Preparations
Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain.
Neonc Technologies Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$2.14 |
| Cash and investments | $0.08 |
| Debt | $0.01 |
| Book value | −$0.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | $0.00 | −$0.69 | — | −$0.24 | — | −$0.30 |
| 2025 | $0.00 | −$3.20 | $0.02 | −$0.95 | — | −$0.80 |